Omega-3 fatty acid ethyl esters (Omacor®) for the treatment of hypertriglyceridemia

Future Lipidology

Volumn 2, Issue 3, 2007, Pages 263-270

  Bhatnagar, Deepak ^a   Hussain, Fatima ^b  

^a ROYAL OLDHAM HOSPITAL   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

Hypertriglyceridaemia; Omacor ; Omega 3 fatty acids; Triglycerides

Indexed keywords

ACIPIMOX; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ATORVASTATIN; COLESTIPOL; COLESTYRAMINE; DOCOSAHEXAENOIC ACID; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHENYTOIN; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL;

ARTICLE; BLEEDING TIME; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; DIABETIC PATIENT; DIARRHEA; DISEASE SEVERITY; DRESSLER SYNDROME; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; ENDOTHELIUM; ERUCTATION; EUROPE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOGLOBULIN A NEPHROPATHY; MONOTHERAPY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SUDDEN DEATH; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL;

DELLA;

EID: 34250379960     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.2.3.263     Document Type: Article

References (58)

1. Castelli WP, Garrison RJ, Wilson PW et al.: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 256, 2835-2838 (1986).
2. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV: Clinical relevance of postprandial lipaemia. Curr. Med. Chem. 12, 1931-1945 (2005).
3. Durrington PN: Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis 141(Suppl. 1), S57-S62 (1998).
4. Bhatnagar D: Hypertriglyceridaemia. In: Lipoproteins in Health and Disease (Betteridge, Illingworth, Shepherd (Eds). Edward Arnold, London, UK 737-751 (1999).
5. Griffin BA, Minihane AM, Furlonger N et al.: Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects. Clin. Sci. 97, 269-276. (1999).
6. Stein EA, Lane M, Laskarzewski P: comparisons of statins in hypertriglyceridaemia. Am. J. Cardiol. 81, 66B-69B. (1998).
7. Jones PH, Davidson MH, Stein EA et al.: STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92, 152-160 (2003).
8. Harris WS: Omega-3 long chain fatty PUFA and triglyceride-lowering: minimum effective intakes. Eur. Heart J. 3(Suppl. D), D59-D61 (2001).
9. Bhatnagar D, Durrington PN: Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int. J. Clin. Pract. 57(4), 305-314 (2003).
10. Simopoulos AP: Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 21, 495-505 (2002).
11. Heller A, Koch T, Schmeck J, van Ackern K: Lipid mediators in inflammatory disorders. Drugs 55, 487-496 (1998).
12. Ukropec J, Reseland JE, Gasperikova D: The hypotriglyceridemic effect of dietary n-3 FA is associated with increased β-oxidation and reduced leptin expression. Lipids 38, 1023-1029 (2003).
13. Mori TWG, Burke V, Hilme E, Puddey I, Beilin L: Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 102, 1264-1269 (2000).
14. von Schacky C: Dietary omega-3 fatty acids and human growth factor and cytokine gene expression. Eur. Heart J. 200, 3(Suppl. D), D50-D52 (2001).
15. Price PT, Nelson CM, Clarke SD: Omega-3 polyunsaturated fatty acid regulation of gene expression. Curr. Opin. Lipidol. 11, 3-7 (2000).
16. Leaf A, Kang JX: Prevention of cardiac sudden death by N-3 fatty acids: a review of the evidence. J. Intern. Med. 240, 5-12 (1996).
17. De Caterina R, Basta G: N-3 fatty acids and the inflamatory response-biological background. Eur. Heart J. 3(Suppl. D), D42-D49 (2001).
18. Harris WS, Windsor SL, Caspermeyer JJ: Modification of lipid-related atherosclerosis risk factors by Omega-3 fatty acid ethyl esters in hypertriglyceridemic patients. J. Nutr. Biochem. 4, 706-712 (1993).
19. Davidson MH: Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am. J. Cardiol. 98(Suppl. 1), 27-33 (2006).
20. Chan DC, Watts GF, Mori TA, Barrett PH, Redgrave TG, Beilin LJ: Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am. J. Clin. Nutr. 77, 300-307 (2003).
21. Bordin P, Bodamer OA, Venkatesan S, Gray RM, Bannister PA, Halliday D: Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males. Eur. J. Clin. Nutr. 52, 104-109 (1998).
22. Kasim-Karakas SE, Herrmann R, Almario R: Effects of omega-3 fatty acids on intravascular lipolysis of very-low-density lipoproteins in humans. Metabolism 44, 1223-1230 (1995).
23. Pownall HJ, Brauchi D, Kilinc C et al.: Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 143, 285-297 (1999).
24. Mori TA, Burke V, Puddey IB et al.: Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am. J. Clin. Nutr. 71, 1085-1094 (2000).
25. Griffin BA: The effect of n-3 fatty acids on low density lipoprotein subfractions. Lipids 36(Suppl. 1) S91-S97 (2001).
26. Bakewell L, Burdge GC, Calder PC: Polyunsaturated fatty acid concentrations in young men and women consuming their habitual diets. Br. J. Nutr. 96, 93-99 (2006).
27. Eritsland J, Arnesen H, Smith P, Seljeflot I. Dahl K: Effects of highly concentrated omega-3 polyunsaturated fatty acids and acetylsalicylic acid, alone and combined, on bleeding time and serum lipid profile. J. Oslo City Hosp. 39(8-9), 97-101 (1989).
28. Hansen JB, Lyngmo V, Svensson B, Nordoy A: Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa). Arterioscler. Thromb. 13(1), 98-104 (1993).
29. Krokan HE, Bjerve KS, Mork E: The enteral bioavailability of eicosapentaenoic acid and docosahexaenoic acid is as good from ethyl esters as from glyceryl esters in spite of lower hydrolytic rates by pancreatic lipase in vitro. Biochim. Biophys. Acta. 20, 1168(1), 59-67 (1993).
30. Lungershausen YK, Abbey M, Nestel PJ, Howe PR: Reduction of blood pressure and plasma triglycerides by omega-3 fatty acids in treated hypertensives. J. Hypertens. 12(9), 1041-1045 (1994).
31. Mackness MI, Bhatnagar D, Durrington PN et al.: Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur. J. Clin. Nutr. 48(12), 859-865 (1994).
32. Soyland E, Funk J, Rajka G et al.: Dietary supplementation with very long-chain n-3 fatty acids in patients with atopic dermatitis. A double-blind, multicentre study. Br. J. Dermatol. 130, 757-764 (1994).
33. Grundt H, Nilsen DW, Hetland O et al.: Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia. J. Intern. Med. 237(3), 249-259 (1995).
34. Eritsland J, Arnesen H, Gronseth K et al.: Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am. J. Cardiol. 77, 31-36 (1996).
35. Harris WS, Ginsberg HN, Arunakul N et al.: Safety and efficacy of Omacor in severe hypertriglyceridemia. J. Cardiovasc. Risk 4(5-6), 385-391 (1997).
36. McKeone BJ, Osmundsen K, Brauchi D et al.: Alterations in serum phosphatidylcholine fatty acyl species by eicosapentaenoic and docosahexaenoic ethyl esters in patients with severe hypertriglyceridaemia. J. Lipid Res. 38, 429-436 (1997).
37. Abe Y, El-Masri B, Kimball KT et al.: Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler: Thromb. Vasc. Biol. 18(5), 723-731 (1998).
38. Borthwick L et al.: The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia. Clin. Drug Invest. 15, 397-404 (1998).
39. Nordoy A, Bonaa KH, Nilsen H et al.: Effects of simvastatin and omega-3 fatty acids on plasma lipoprotein and lipid peroxidation in patients with combined hyperlipidaemia. J. Int. Med. 243, 163-170 (1998).
40. Swahn E, von Schenck H, Olsson AG: Omega-3 ethyl ester concentrate decreases total apolipoprotein cIII and increases antithrombin III in postmyocardial infarction patients. Clin. Drug Investig. 15, 473-482 (1998).
41. Johansen O, Brekke M, Seljeflot I, Abdelnoor M, Arnesen H: N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial. J. Am. Coll. Cardiol. 33(6), 1619-1626 (1999).
42. Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 148(2), 387-396 (2000).
43. Goodfellow J, Bellamy MF, Ramsey MW et al.: Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J. Am. Coll. Cardiol. 35, 265-70 (2000).
44. Stalenhoef AF, de Graaf J, Wittekoek ME, Bredie SJ, Demacker PN, Kastelein JJ: The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis 153(1), 129-138 (2002).
45. Westphal S, Orth M, Ambrosch A, Osmundsen K, Luley C: Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am. J. Clin. Nutr.. 71, 914-920 (2000).
46. Donadio JV, Grande JP: The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin. Nephrol. 24(3), 225-243 (2004).
47. Donadio JV Jr, Larson TS, Bergstralh EJ, Grande JP: A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J. Am. Soc. Nephrol. 12(4), 791-799 (2001).
48. Durrington PN, Bhatnagar D, Mackness MI et al.: An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 85(5), 544 (2001).
49. van Dam M, Stalenhoef AFH, Wittekoek J, Trip MD, Prins MH, Kastelein JJP: Efficacy of concentrated n-3 fatty acids in hypertriglyceridaemia. A comparison with gemfibrozil. Clin. Drug Invest. 3, 175-181 (2001).
50. Chan DC, Watts GF, Mori TA, Barret HR, Redgrave TG, Beilin LJ: Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with viscera lobesity. Am. J. Clin. Nutr. 77, 300-307 (2003).
51. Calabresi L, Villa B, Canavesi M et al.: An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 53(2), 153-158 (2004).
52. Parinyasiri U, Ong-Ajyooth L, Parichatikanond P, Ong-Ajyooth S, Liammongkolkul S, Kanyog S: Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy. J. Med. Assoc. Thai. 87(2), 143-149 (2004).
53. Lee KW, Blann AD, Lip GY: Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction. Thromb Res. 118(3), 305-312 (2006).
54. Patel JV, Lee KW, Tomson J, Dubb K, Hughes EA, Lip GY: Effects of omega-3 polyunsaturated fatty acids on metabolically active hormones in patients post-myocardial infarction. Int. J. Cardiol. 115, 42-45 (2007).
55. Bays H: Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am. J. Cardiol. 98(4A), 71i-76i. (2006).
56. von Schacky C, Weber PC: Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J. Clin. Invest. 76, 2446-2450 (1985).
57. Sinclair HM: Deficiency of essential fatty acids and atherosclerosis. Lancet 2, 117-119 (1978).
58. Bhatnagar D, Mackness MI, Durrington PN: Treatment of mixed hyperlipidaemia using a combination of omega-3 fatty acids and HMG CoA reductase inhibitor Eur. Heart J. 3(Suppl. 3), D53-D58 (2001).